# Englumafusp alfa

Source: https://onco.cc/drugs/englumafusp-alfa/  
OnCo record `englumafusp-alfa` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Englumafusp alfa is an experimental fusion protein from Hoffmann-La Roche in phase 2 trials for hodgkin lymphoma, aimed at CD19.

## Summary

Englumafusp alfa (RO7227166) is a fusion protein developed by Hoffmann-La Roche. Its target is CD19 (the sponsor names CD19 x 4-1BBL). The sponsor states: Englumafusp alfa (RO7227166) is a CD19-targeted 4-1BB ligand fusion protein that costimulates T cells, given by intravenous infusion three-weekly in combination with obinutuzumab and/or glofitamab in relapsed/refractory B-cell non-Hodgkin lymphoma. ClinicalTrials.gov describes the intervention as: Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT04077723, plans to enrol 498 participants with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: A CD19 Targeted 4-1BB Ligand; RO7227166
- Tags: pipeline; ctgov-ingest
- Code: RO7227166
- Modality: fusion protein
- Mechanism: Englumafusp alfa (RO7227166) is a CD19-targeted 4-1BB ligand fusion protein that costimulates T cells, given by intravenous infusion three-weekly in combination with obinutuzumab and/or glofitamab in relapsed/refractory B-cell non-Hodgkin lymphoma.

## Sources

- ClinicalTrials.gov: trials of Englumafusp alfa: https://clinicaltrials.gov/search?intr=RO7227166

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- trials: [A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi](https://onco.cc/trials/nct04077723/)

---
JSON: https://onco.cc/api/v1/entities/englumafusp-alfa.json